A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222

CONCLUSION: Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy number variations in CTC was demonstrated.PMID:34844978 | DOI:10.1158/1078-0432.CCR-21-3131
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research